Literature DB >> 9569027

Stable reintroduction of wild-type P53 (MTmp53ts) causes the induction of apoptosis and neuroendocrine-like differentiation in human ductal pancreatic carcinoma cells.

D Lang1, S J Miknyoczki, L Huang, B A Ruggeri.   

Abstract

Pancreatic ductal adenocarcinoma is one of the major causes of cancer mortality in the industrialized world, having among the poorest prognosis of any malignancy. Mutations or alterations in the p53 tumor suppressor gene/protein are observed in 50-70% of these cancers, yet little information is available regarding the phenotypic effects of restoration of wild-type (wt) p53 function in pancreatic ductal carcinoma cells. The consequences of stable reintroduction of wt p53 on apoptosis and differentiation was examined in a poorly differentiated pancreatic carcinoma cell line (Panc-1), possessing only mutant (mt) p53 (codon 273 mutation). Cells were transfected with a temperature-sensitive mouse p53val135 (tsp53) vector under additional control of a genetically-modified metallothionein promoter. This tsp53 has a 'mt' phenotype at 37.5 degrees C, and a 'wt' phenotype at 32.5 degrees C and the presence of 100 microM ZnCl2. Stable expression of wt p53 caused upregulation of the p21/WAF1 gene, and G1 growth arrest as shown by flow cytometry and BrdU labeling. Additionally, apoptosis was induced 8-12 post-induction in the majority of the cells (60-70%), as demonstrated by morphological changes, in situ TdT labeling and internucleosomal laddering. However, a subpopulation (30%) of the transfectants survived this apoptotic fate. Unlike the epithelial parental Panc-1 cells, these cells exhibited the appearance of a neuroendocrine-like phenotype with extensive branch-like processes, and marked cytoplasmic and cytoskeletal immunostaining for tau-2, synaptophysin, and chromogranin A. These studies suggest that stable and regulated expression of wt p53 can have multiple phenotypic consequences (apoptosis and altered differentiation to a neuroendocrine-like phenotype) in poorly-differentiated pancreatic carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9569027     DOI: 10.1038/sj.onc.1201665

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

1.  Comparison of mutant and wild-type p53 proteins in Merkel cell carcinoma.

Authors:  H J Carson; N E Lueck; B C Horten
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

2.  Ikaros induces quiescence and T-cell differentiation in a leukemia cell line.

Authors:  Katie L Kathrein; Rachelle Lorenz; Angela Minniti Innes; Erin Griffiths; Susan Winandy
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

Review 3.  The potential for gene therapy in pancreatic cancer.

Authors:  M J Humphreys; W Greenhalf; J P Neoptolemos; P Ghaneh
Journal:  Int J Pancreatol       Date:  1999-08

4.  p53, Stem Cells, and Reprogramming: Tumor Suppression beyond Guarding the Genome.

Authors:  Benjamin T Spike; Geoffrey M Wahl
Journal:  Genes Cancer       Date:  2011-04

5.  Retinoic acid can induce markers of endocrine transdifferentiation in pancreatic ductal adenocarcinoma: preliminary observations from an in vitro cell line model.

Authors:  T H El-Metwally; M R Hussein; S Kh Abd-El-Ghaffar; M M Abo-El-Naga; A B Ulrich; P M Pour
Journal:  J Clin Pathol       Date:  2006-02-10       Impact factor: 3.411

6.  The proline TP53 variant stimulates likely lymphangiogenesis in an orthotopic mouse model of pancreatic cancer.

Authors:  N Otto; P Schulz; A Scholz; P Hauff; B Schlegelberger; K M Detjen; B Wiedenmann
Journal:  Br J Cancer       Date:  2011-12-06       Impact factor: 7.640

7.  Inhibition of Neddylation Modification Sensitizes Pancreatic Cancer Cells to Gemcitabine.

Authors:  Hua Li; Weihua Zhou; Lihui Li; Jianfu Wu; Xiaoli Liu; Lili Zhao; Lijun Jia; Yi Sun
Journal:  Neoplasia       Date:  2017-05-20       Impact factor: 5.715

8.  Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63.

Authors:  Toshinori Ozaki; Mizuyo Nakamura; Takehiro Ogata; Meijie Sang; Hiroyuki Yoda; Kiriko Hiraoka; Meixiang Sang; Osamu Shimozato
Journal:  Oncotarget       Date:  2016-11-01

9.  Chemotherapy synergizes with radioimmunotherapy targeting La autoantigen in tumors.

Authors:  Fares Al-Ejeh; Jocelyn M Darby; Michael P Brown
Journal:  PLoS One       Date:  2009-02-27       Impact factor: 3.240

10.  Differential roles of ERRFI1 in EGFR and AKT pathway regulation affect cancer proliferation.

Authors:  Junmei Cairns; Brooke L Fridley; Gregory D Jenkins; Yongxian Zhuang; Jia Yu; Liewei Wang
Journal:  EMBO Rep       Date:  2018-01-15       Impact factor: 8.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.